2-甲基-1-(苯基甲基)肼 | 10309-79-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-1-(苯基甲基)肼
• 英文名称: 1-benzyl-2-methylhydrazine
• 英文别名: N-benzyl-N'-methyl-hydrazine；N-Benzyl-N'-methyl-hydrazin；N-Methyl-N'-benzyl-hydrazin；1-Methyl-2-benzyl-hydrazin；1-Benzyl-2-methylhydrazin；2-Benzyl-1-methylhydrazin
• CAS: 10309-79-2
• 化学式: C₈H₁₂N₂
• mdl: MFCD01722687
• 分子量: 136.197
• InChiKey: HDCUSMZVZWLDRZ-UHFFFAOYSA-N

物化性质

• 熔点：
  59-61 °C
• 沸点：
  240.49°C (rough estimate)
• 密度：
  1.0348 (rough estimate)
• 颜色/状态：
  Yellow crystals
• 溶解度：
  In water, 8,665 mg/L at 25 °C /Estimated/
• 蒸汽压力：
  0.09 mm Hg at 25 °C /Estimated/
• 分解：
  When heated to decomposition it emits toxic fumes of /nitrogen oxides/.

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

ADMET

代谢

大鼠肝脏和肺部的酶系统负责氧化代谢肼衍生物，本研究旨在确定这些酶，细胞色素P450和单胺氧化酶，是否负责代谢激活肼成为致癌/有毒代谢物。细胞色素P450优先氧化1,2-二取代肼和肼酯中的氮-氮键，而单胺氧化酶氧化所有测试的肼衍生物类别中的氮-氮键。氮-氮键的氧化导致1,2-二取代肼的情况下形成稳定的偶氮中间体，而在单取代肼和肼酯的情况下则形成不稳定的单偶氮（重氮烯）代谢物。/取代肼/

The enzyme systems in rat liver and lung responsible for the oxidative metabolism of hydrazine derivatives were studied to determine whether these enzymes, cytochrome p450 and monoamine oxidase, were responsible for metabolically activating hydrazines to carcinogenic/toxic metabolites. Cytochrome p450 preferentially oxidized the nitrogen to nitrogen bond of 1,2-disubstituted hydrazines and hydrazides, while monoamine oxidase oxidized the nitrogen to nitrogen bond of all the classes of hydrazine derivatives that were tested. Oxidation of the nitrogen to nitrogen bond led to the formation of stable azo intemediates in the case of 1,2-disubstituted hydrazines and to unstable monoazo (diazene) metabolites in the case of monosubstituted hydrazines and hydrazides. /Substituted hydrazines/

来源:Hazardous Substances Data Bank (HSDB)

代谢

研究了苯巴比妥预处理的大鼠肝微粒体对普罗卡巴嗪及其偶氮、腙和两种偶氮氧衍生物以及甲肼的氧化代谢，以阐明普罗卡巴嗪产生甲烷的代谢途径。当与富含NADPH的微粒体反应混合物一起孵化时，除了偶氮异构体之外的所有化合物都被代谢产生甲烷。普罗卡巴嗪在形成甲烷时出现了滞后期，而其他化合物则没有。利用甲眯唑和乙基肼的动力学和抑制研究表明，甲肼不是普罗卡巴嗪形成甲烷的中间体。当偶氮衍生物在肝微粒体存在下进行氧化代谢时，没有检测到腙的互变异构体。在监测普罗卡巴嗪微粒体代谢过程中形成的偶氮和腙代谢物时，发现偶氮衍生物的生成量足以解释大部分产生的甲烷。此外，还检测到了少量的腙。因此得出结论，普罗卡巴嗪的偶氮和腙代谢物都从肼的末端甲基团贡献于甲烷的形成，其中偶氮衍生物是主要的甲烷来源，而腙衍生物是次要的甲烷来源。讨论了普罗卡巴嗪氧化的化学和酶促途径，以及甲基自由基中间体在甲烷形成中的意义。

The oxidative metabolism of procarbazine, its azo, hydrazone, and two azoxy derivatives, and methylhydrazine by hepatic microsomes from phenobarbital-pretreated rats was investigated to elucidate the pathway of metabolism that resulted in methane formation from procarbazine. When incubated with microsomal reaction mixtures fortified with NADPH, all of the compounds, except the azoxy isomers, were metabolized to yield methane. A lag phase in methane formation was noted for procarbazine, but not for the other compounds. Kinetic and inhibition studies utilizing methimazole and ethylhydrazine precluded methylhydrazine as an intermediate in methane formation from procarbazine. When the azo derivative was oxidatively metabolized in the presence of liver microsomes, no hydrazone tautomer was detected. Upon monitoring the production of the azo and hydrazone metabolites formed during microsomal metabolism of procarbazine, the azo derivative was formed in sufficient quantities to account for the majority of the methane produced. In addition, small amounts of hydrazone were also detected. It was concluded that both the azo and hydrazone metabolites of procarbazine contribute to methane formation from the terminal methyl group of the hydrazine with the azo derivative being the predominant source and the hydrazone derivative being a minor source of methane. Consideration of the chemical and enzymatic pathways of procarbazine oxidation and the implication of a methyl radical intermediate in methane formation are discussed.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 副作用

神经毒素 - 其他中枢神经系统神经毒素

Neurotoxin - Other CNS neurotoxin

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 解毒与急救

暴露的特定处理方法包括用肥皂和水彻底清洗所有暴露的皮肤区域，大量冲洗眼睛，以及迅速将患者从暴露源移开。/肼/

Specific treatment for exposure consists of thorough washing of all exposed skin areas with soap and water, copious irrigation of the eyes, and prompt removal of the patient from the source of exposure. /Hydrazines/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

经吸入后，需要观察是否出现进行性呼吸窘迫。应监测胸部X光和动脉血气。可能需要给予氧气、插管和辅助通气。需要排除肺炎和支气管炎。/联胺/

After inhalation, observation for progressive respiratory distress is necessary. Chest X-ray and arterial blood gases should be monitored. Administration of oxygen, intubation, and assisted ventilation may become necessary. Pneumonia and bronchitis need to be excluded. /Hydrazines/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

维生素B6可能具有解毒作用。...应该使用地西泮、苯妥英或苯巴比妥来控制癫痫发作。应该监测血糖水平以发现严重的低血糖，这可能在有或没有先前显著高血糖的情况下出现。应该观察患者是否有血管内溶血的迹象、高铁血红蛋白血症以及随之而来的肾功能恶化。对于有症状的患者或者高铁血红蛋白水平超过30%的患者，应该使用亚甲基蓝1至2毫克/公斤，缓慢静脉注射，每4小时根据需要给药。如果诊断正确，改善是显著的。应该监测肝功能，因为肼类是已知的肝毒素。/肼类/

Pyridoxine may be antidotal. ...Seizures should be controlled with diazepam, phenytoin, or phenobarbital. Blood sugar levels should be monitored for severe hypoglycemia, which may appear with or without preceding significant hyperglycemia. The patient should be observed for evidence of intravascular hemolysis, methemoglobinemia, and consequent deterioration of renal function. Patients who are symptomatic or who demonstrate a methemoglobin level greater than 30 per cent should be treated with methylene blue 1 to 2 mg per kg slowly IV every 4 hours as needed. Improvement is dramatic if diagnosis is correct. Liver function should be monitored because hydrazines are known hepatotoxins. /Hydrazines/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

消散可以通过强迫性利尿和尿液酸化来增强。血液透析和腹膜透析应该是有效的，但关于使用这些方法的不足人类数据存在。否则，治疗是症状性的和支持性的。/肼/

Elimination is enhanced by forced diuresis and acidification of the urine. Hemodialysis and peritoneal dialysis should be effective, but insufficient human data exist on the use of these modalities. Treatment is otherwise symptomatic and supportive. /Hydrazines/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  2-甲基-1-(苯基甲基)肼 在 溶剂黄146 、 sodium nitrite 作用下， 生成 N'-benzyl-N-methyl-N-nitroso-hydrazine
  参考文献：
  名称：

  Thiele, Justus Liebigs Annalen der Chemie, 1910, vol. 376, p. 255

  摘要：

  DOI：
• 作为产物：
  描述：

  在 盐酸 作用下， 以 水 为溶剂， 反应 0.17h， 生成 2-甲基-1-(苯基甲基)肼
  参考文献：
  名称：

  通过吖嗪的高压烷基化制备 N-烷基-和 N,N"-二烷基肼的新途径

  摘要：

  研究了卤代烷与对硝基苯甲醛、苯甲醛和对甲氧基苯甲醛的吖嗪在高压 (10 kbar) 下的反应。取决于起始吖嗪的结构和溶剂性质，反应混合物的水解以高产率得到纯的 N-单烷基-或 N,N"-二烷基肼。发现非对称 N,N"-二烷基肼可以是在不分离中间体 N-单季铵盐的情况下合成。讨论了溶剂相变对烷基化方向的影响。

  DOI：

  10.1023/b:rucb.0000035662.78900.7c

文献信息

• An infrared spectroscopic method of distinguishing isomeric disubstituted hydrazines as salts
  作者：J. A. Blair、R. J. Gardner

  DOI：10.1039/j39700002707

  日期：——

  Isomeric 1,1- and 1,2-disubstituted hydrazines may be readily distinguished by examination of the NH stretching frequencies in the i.r. spectra of their hydrochloride salts.

  通过检查它们的盐酸盐的IR光谱中的NH拉伸频率，可以容易地区分异构的1，1-和1，2-二取代的肼。
• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
  申请人：Board of Regents, The University of Texas System

  公开号：US20210154204A1

  公开（公告）日：2021-05-27

  Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

  本文披露了抑制RIPK1的化合物，包括药物组合物和治疗RIPK1介导的疾病的方法，如神经退行性疾病、炎症性疾病和癌症。
• Compounds
  申请人：Ford John

  公开号：US20070161672A1

  公开（公告）日：2007-07-12

  Thienopyridine compounds which are potassium channel inhibitors are described. Pharmaceutical compositions comprising the compounds and their use in the treatment or prevention of cancer, arrhythmias, autoimmune diseases and inflammatory diseases, including gastric cancer, atrial fibrillation, type-2 diabetes mellitus, rheumatoid arthritis, type-1 diabetes, inflammatory bowel disorder and demyelinating disorders such as multiple sclerosis are also disclosed.

  描述了一种钾通道抑制剂的噻吡啶类化合物。还披露了包括这些化合物的药物组合物以及它们在治疗或预防癌症、心律失常、自身免疫疾病和炎症性疾病中的用途，包括胃癌、心房颤动、2型糖尿病、类风湿性关节炎、1型糖尿病、炎症性肠道疾病和多发性硬化等脱髓鞘疾病。
• [EN] MODIFIED DNA-ENCODED CHEMICAL LIBRARY AND METHODS RELATED THERETO<br/>[FR] BIBLIOTHÈQUE CHIMIQUE D'ADN CODÉ MODIFIÉ ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV DORTMUND TECH

  公开号：WO2021191333A1

  公开（公告）日：2021-09-30

  The present invention relates to a compound library comprising a plurality of conjugate molecules, wherein said conjugates comprise a small organic molecule covalently coupled to a nucleic acid moiety, wherein the nucleic acid moiety comprises or consists of 7-deazapurines and/or 7-deaza-8-azapurines, and, optionally, modified and/or unmodified pyrimidine nucleotides. Further, the present invention relates to the use of said library for screening compounds binding to a target molecule and methods of synthesizing said library.

  本发明涉及一种化合物库，其中包含多个共轭分子，所述共轭物包含一个小有机分子与一个核酸基团共价耦合，其中核酸基团包含或仅包含7-脱氮嘌呤和/或7-脱氮-8-氮杂嘧啶，以及可选的修饰和/或未修饰的嘧啶核苷酸。此外，本发明还涉及使用该库筛选与目标分子结合的化合物和合成该库的方法。